Results 71 to 80 of about 14,298 (222)

La gD2 coadministrada con el AFCo1 por vía intranasal induce inmunidad protectora contra virus de herpes simple tipo 2 en ratones

open access: yesVacciMonitor, 2012
La infección por virus herpes simple tipo 2 (VHS-2) continúa siendo un problema de salud mundial. Esta infección es transmitida sexualmente y es la principal causa de úlceras genitales.
Osmir Cabrera   +11 more
doaj  

Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform

open access: yesAdvanced Science
Disialoganglioside‐GD2 is a key molecular target for Neuroblastoma (NB) immunotherapy based on the employment of GD2‐targeting antibodies. However, about 50% of treated patients can experience tumor relapse due to limited immune‐mediated cytotoxicity and
Suleman Khan Zadran   +25 more
doaj   +1 more source

Effects of proton therapy on the tumor immune system and clinical implications: A review

open access: yesPrecision Radiation Oncology, EarlyView.
Proton therapy is a novel radiotherapy technique. We review four aspects of proton therapy: application in various tumors, effects on the tumor immune system, combination with other therapies, and future challenges. By presenting these aspects in this review, we aim to inspire clinical interventions.
Rundong Liu   +5 more
wiley   +1 more source

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

open access: yes, 2023
Background: Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. Methods: In an academic, phase 1-2
M. Guercio   +34 more
core   +2 more sources

Functional activity of anti-GD2 CAR-T cells with different antigen-recognition module

open access: yesМедицинская иммунология
Neuroblastoma (NB) is the most common extracranial solid tumor in children comprising, 8 to 10% of all pediatric tumors, with incidence of about 1-1.3 cases per 100,000 children under 15 years of age.
D. V. Lutskovich   +4 more
doaj   +1 more source

Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. [PDF]

open access: yesPLoS ONE, 2015
Gaucher disease (GD) is caused by insufficient activity of acid β-glucosidase (GCase) resulting from mutations in GBA1. To understand the pathogenesis of the neuronopathic GD, induced pluripotent stem cells (iPSCs) were generated from fibroblasts ...
Ying Sun   +11 more
doaj   +1 more source

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du   +9 more
wiley   +1 more source

GD2 Expression in canine primary tumors.

open access: yes, 2021
Frozen sections of canine tissues labeled with anti-GD2 mAb (clone 14.G2a, a murine IgG2a anti-GD2 mAb) conjugated to PE (red) and counter-stained with DAPI (blue).
Zachary S. Morris (6287090)   +17 more
core   +1 more source

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

GD2-Specific CAR T Cells Demonstrate Potent and Targeted Anti-Tumor Efficacy Against Melanoma In Vitro and In Vivo

open access: yesFrontiers in Bioscience-Landmark
Background: Disialoganglioside (GD2) is a tumor-associated antigen that is highly expressed in various neuroectodermal cancers, including melanoma.
Julia Philippova   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy